Leading the project are Dr. Mone Zaidi from Icahn Mount Sinai and Dr. Clifford J. Rosen from the MaineHealth Institute for Research.
Previous research from Dr. Ziadi indicates that inhibiting FSH increases bone mass and reduces body fat and neurodegeneration. Continuing research regarding this aging-related hormone could pave the way for new treatments for associated conditions like obesity, osteoporosis, menopause and Alzheimer’s disease.
The funding is provided by the National Institutes of Health and will be awarded annually in increments of $4.2 million for the next five years.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
